Cannabist Company Holdings Past Earnings Performance
Past criteria checks 0/6
Cannabist Company Holdings's earnings have been declining at an average annual rate of -38.1%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 41.7% per year.
Key information
-38.1%
Earnings growth rate
-21.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 41.7% |
| Return on equity | -266.7% |
| Net Margin | -34.4% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Cannabist Company Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 511 | -176 | 164 | 0 |
| 30 Sep 23 | 509 | -403 | 185 | 0 |
| 30 Jun 23 | 513 | -402 | 194 | 0 |
| 31 Mar 23 | 513 | -427 | 209 | 0 |
| 31 Dec 22 | 512 | -416 | 218 | 0 |
| 30 Sep 22 | 525 | -169 | 226 | 0 |
| 30 Jun 22 | 524 | -177 | 220 | 0 |
| 31 Mar 22 | 497 | -141 | 208 | 0 |
| 31 Dec 21 | 460 | -143 | 196 | 0 |
| 30 Sep 21 | 397 | -131 | 186 | 0 |
| 30 Jun 21 | 313 | -98 | 170 | 0 |
| 31 Mar 21 | 239 | -104 | 152 | 0 |
| 31 Dec 20 | 180 | -96 | 136 | 0 |
| 30 Sep 20 | 127 | -81 | 130 | 0 |
| 30 Jun 20 | 100 | -88 | 130 | 0 |
| 31 Mar 20 | 91 | -98 | 128 | 0 |
| 31 Dec 19 | 77 | -96 | 124 | 0 |
| 30 Sep 19 | 65 | -97 | 102 | 0 |
| 30 Jun 19 | 53 | -84 | 84 | 0 |
| 31 Mar 19 | 43 | -54 | 63 | 0 |
| 29 Dec 18 | 39 | -39 | 51 | 0 |
| 29 Sep 18 | 36 | -15 | 42 | 0 |
| 30 Dec 17 | 29 | 3 | 37 | 0 |
| 31 Dec 16 | 18 | -9 | 23 | 0 |
Quality Earnings: VW5 is currently unprofitable.
Growing Profit Margin: VW5 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VW5 is unprofitable, and losses have increased over the past 5 years at a rate of 38.1% per year.
Accelerating Growth: Unable to compare VW5's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VW5 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: VW5 has a negative Return on Equity (-266.69%), as it is currently unprofitable.